Biblio Discovery — Demo Discovery Service

12 results for "Heather Y. Lin"

Showing 1–12 · 0.29 seconds · RSS

  1. Journal Article

    Psychosocial Determinants of Total Knee Arthroplasty Outcomes Two Years After Surgery

    Maria A. Lopez‐Olivo; Aparna Ingleshwar; Glenn C. Landon et al.

    ACR Open Rheumatology, Vol. 2 No. 10 · 2020 · English · DOAJ Scopus

    Objective To evaluate the association of preoperative psychosocial and demographic factors with total knee arthroplasty (TKA) outcomes and satisfaction in patients with osteoarthritis (OA) of the knee at 24 months after surgery. Methods A prospective cohort study of patients undergoing TKA was…

  2. Journal Article

    Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data

    Ji Son; Rodney Cheng-En Hsieh; Heather Y. Lin et al.

    Frontiers in Immunology, Vol. 13 · 2022 · English · DOAJ Scopus

    CD47-SIRPα interaction acts as a “don’t eat me” signal and is exploited by cancer to downregulate innate and adaptive immune surveillance. There has been intense interest to develop a mechanism of blockade, and we aimed to analyze the emerging data from early clinical trials. We performed a…

  3. Journal Article

    Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastases

    Eswaran Devarajan; R. Eric Davis; Hannah C. Beird et al.

    Discover Oncology, Vol. 15 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Lung metastases are the primary cause of death for osteosarcoma (OS) patients. We recently validated interleukin-11 receptor α (IL-11Rα) as a molecular target for the inhibition of OS lung metastases. Since there is no clinically approved antibody against this receptor, we sought to…

  4. Journal Article Full text

    Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells

    Yun-Ju Chen; Wei-Chien Huang; Ya-Ling Wei et al.

    PLoS ONE, Vol. 6 No. 6 · 2011 · English · PLOS Scopus

    Background: The sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not as sensitive as patients harboring these mutations, some patients with wild-type EGFR (wtEGFR) remain responsive…

    Also available at: DOAJ

  5. Journal Article

    Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson

    Jeong Uk Lim; Heather Y. Lin; Lei Kang et al.

    npj Precision Oncology, Vol. 10 No. 1 · 2026 · English · DOAJ Scopus

    Abstract We evaluated clinical outcomes and safety profiles in patients with non-small cell lung cancer (NSCLC) treated in early-phase trials. A retrospective review of 546 NSCLC cases treated from January 2016 to December 2024 at The University of Texas MD Anderson Cancer Center was performed…

  6. Journal Article

    Coronary Stent Healing in Cancer Patients—An Optical Coherence Tomography Perspective

    Moez Karim Aziz; Joerg Herrmann; Konstantinos Marmagkiolis et al.

    Frontiers in Cardiovascular Medicine, Vol. 8 · 2021 · English · DOAJ Scopus

    Objective: This study assessed stent healing patterns and cardiovascular outcomes by optical coherence tomography (OCT) in cancer patients after drug-eluting stent (DES) placement.Background: Cancer treatment, owing to its cytotoxic and antiproliferative effects, could delay stent healing and…

  7. Journal Article Full text

    Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

    Ji Son; Heather Y. Lin; Siqing Fu et al.

    Journal of Immunotherapy and Precision Oncology, Pp 10-18 (2023) · 2023 · English · DOAJ Scopus

    Introduction: We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to phase I clinical trials. Methods: Patients with cervical cancer who received at least one dose of a phase I investigational agent…

  8. Journal Article

    Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer

    Steven H Lin; Heather Y Lin; Vivek Verma et al.

    Cancer Treatment and Research Communications, Vol. 30 · 2022 · English · DOAJ Scopus

    ABSTRACT: OBJECTIVE: This phase I trial (NCT01912625) evaluated the safety and pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic non-small cell lung cancer (NSCLC). METHODS: Patients received cCRT…

  9. Journal Article

    Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

    Tina Cascone; Annikka Weissferdt; Myrna C. B. Godoy et al.

    Nature Communications, Vol. 12 No. 1 · 2021 · English · DOAJ Scopus

    Granulomatous/sarcoid-like lesions have been reported in patients treated with immune checkpoint inhibitors (ICIs). Here the authors report the occurrence of “nodal immune flare”, an apparent radiological cancer progression in the nodes characterized by the absence of cancer and the presence of…

  10. Journal Article

    Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer

    Charles Lu; Mehmet Altan; Apar Pataer et al.

    Journal for ImmunoTherapy of Cancer, Vol. 12 No. 10 · 2024 · English · DOAJ Scopus

    Background Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the efficacy of neoadjuvant ICIs remains unclear. We report the…

  11. Journal Article

    The immune landscape of undifferentiated pleomorphic sarcoma

    Rossana Lazcano; Carmelia M. Barreto; Ruth Salazar et al.

    Frontiers in Oncology, Vol. 12 · 2022 · English · DOAJ Scopus

    IntroductionUndifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize the immune microenvironment of UPS and its association with…